Starting July 15, 2013, SDIX's life science business became SDIX LLC, a wholly owned subsidiary of OriGene. The content below is archival information for SDIX, Inc., and will be presented for 3 months as reference.
SDIX, Inc., is now Special Diversified Opportunities, Inc. The Antibody Life Sciences division is now SDIX, LLC.
Our last Investor call was held on
Monday, November 12, 2012 at 4:30 PM EST
Click here to listen to the call.
Subject: Q3 2012 Earnings Conference Call
Webcast Replay Available for 90 Days
Click to listen to the live broadcast. An audio replay of the call will be available for 90 days. Telephone replays of the call will be available from 7:30 p.m. ET on November 12, 2012 through 11:59 p.m. ET on November 27, 2012. To listen to the telephone replay, dial 877-660-6853 (201-612-7415 outside the U.S.) and enter account number 286 and conference ID 398583.
SDIX, (Nasdaq: SDIX ) is a biotechnology company with a core expertise in creating better antigens, better antibodies and better assays for the pharmaceutical and biotechnology markets. For over 20 years, SDIX has been a leading immuno-solutions company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives.
In the life science market, SDIX’s technology and capabilities are being used to help discover disease mechanisms, facilitate development of new drugs, and provide antibodies and assays for the diagnosis of disease.
EDGAR SEC filings
2011 Proxy Statement
Investor Relations Contacts
Email SDIX Investor Relations
American Stock Transfer
59 Maiden Lane
New York, NY 10038